Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)
August 14, 2024 6:12 AM EDTBTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).
The analyst comments "Enrolling a trial with a placebo arm when an active commercial drug is available is historically challenging, so we see Acumen's comments about the rapid enrollment of the P2 trial for Sabirnetug as very encouraging. Talking with management, both the therapeutic premise of a safer antibody that may also be more... More
